-
1
-
-
70350180854
-
Top 200 drugs of 2008
-
Lamb E. Top 200 drugs of 2008. Pharmacy Times 2009.
-
(2009)
Pharmacy Times
-
-
Lamb, E.1
-
2
-
-
84857107205
-
-
Accessed April 5, 2010
-
Pfizer 2009 Annual Report Accessed April 5, 2010. http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf.
-
Pfizer 2009 Annual Report
-
-
-
3
-
-
0035897696
-
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults
-
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
-
4
-
-
80051627851
-
-
Kowa Pharmaceuticals America, Inc, Montgomery, Ala
-
Livalo (pitavastatin) [product information] 2009, Kowa Pharmaceuticals America, Inc, Montgomery, Ala.
-
(2009)
Livalo (pitavastatin) [product information]
-
-
-
5
-
-
33748042671
-
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
-
Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
-
(2006)
Pharmacol Ther
, vol.112
, pp. 71-105
-
-
Shitara, Y.1
Sugiyama, Y.2
-
6
-
-
0012908222
-
Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
-
Aoki T., Nishimura H., Nakagawa S., et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
-
(1997)
Arzneimittelforschung
, vol.47
, pp. 904-909
-
-
Aoki, T.1
Nishimura, H.2
Nakagawa, S.3
-
7
-
-
0034570787
-
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells
-
Morikawa S., Umetani M., Nakagawa S., et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000, 7:138-144.
-
(2000)
J Atheroscler Thromb
, vol.7
, pp. 138-144
-
-
Morikawa, S.1
Umetani, M.2
Nakagawa, S.3
-
8
-
-
9144234810
-
Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells
-
Fan P., Zhang B., Kuroki S., Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ J 2004, 68:1061-1066.
-
(2004)
Circ J
, vol.68
, pp. 1061-1066
-
-
Fan, P.1
Zhang, B.2
Kuroki, S.3
Saku, K.4
-
9
-
-
5144220807
-
Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell
-
Maejima T., Yamazaki H., Aoki T., et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
-
(2004)
Biochem Biophys Res Commun
, vol.324
, pp. 835-839
-
-
Maejima, T.1
Yamazaki, H.2
Aoki, T.3
-
10
-
-
26944457749
-
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes
-
Saiki A., Murano T., Watanabe F., et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005, 12:163-168.
-
(2005)
J Atheroscler Thromb
, vol.12
, pp. 163-168
-
-
Saiki, A.1
Murano, T.2
Watanabe, F.3
-
11
-
-
0002549759
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans
-
Fujino H., Kojima J., Yamada Y., Kanda H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans. Drug Metab Pharmacokinetics 1999, 14:79-91.
-
(1999)
Drug Metab Pharmacokinetics
, vol.14
, pp. 79-91
-
-
Fujino, H.1
Kojima, J.2
Yamada, Y.3
Kanda, H.4
-
12
-
-
0000332988
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats
-
Kimata H., Fujino H., Koide H., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Drug Metab Pharmacokinetics 1998, 13:484-499.
-
(1998)
Drug Metab Pharmacokinetics
, vol.13
, pp. 484-499
-
-
Kimata, H.1
Fujino, H.2
Koide, H.3
-
13
-
-
0000332993
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (2): absorption, distribution, metabolism, excretion and accumulation following repeated oral administration of 14C-NK-104 in rats
-
Fujino H., Tsunenari Y., Koide T., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (2): absorption, distribution, metabolism, excretion and accumulation following repeated oral administration of 14C-NK-104 in rats. Drug Metab Pharmacokinetics 1998, 13:499-507.
-
(1998)
Drug Metab Pharmacokinetics
, vol.13
, pp. 499-507
-
-
Fujino, H.1
Tsunenari, Y.2
Koide, T.3
-
14
-
-
0001224909
-
Studies on metabolic fate of NK-104, a new inhibitor of HMG-CoAQ reductase (5): in vitro metabolism and plasma protein binding in animals and humans
-
Fujino H., Yamada I., Kojima J., et al. Studies on metabolic fate of NK-104, a new inhibitor of HMG-CoAQ reductase (5): in vitro metabolism and plasma protein binding in animals and humans. Xenobio Metabol Dispos 1999, 14:415-425.
-
(1999)
Xenobio Metabol Dispos
, vol.14
, pp. 415-425
-
-
Fujino, H.1
Yamada, I.2
Kojima, J.3
-
15
-
-
0032970752
-
Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
-
Kojima J., Fujino H., Yosimura M., et al. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999, 724:173-180.
-
(1999)
J Chromatogr B Biomed Sci Appl
, vol.724
, pp. 173-180
-
-
Kojima, J.1
Fujino, H.2
Yosimura, M.3
-
16
-
-
0032914056
-
Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile
-
Kojima J., Fujino H., Abe H., et al. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 1999, 22:142-150.
-
(1999)
Biol Pharm Bull
, vol.22
, pp. 142-150
-
-
Kojima, J.1
Fujino, H.2
Abe, H.3
-
17
-
-
0001224909
-
Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human
-
Fujino H., Yamada I., Kojima J., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Drug Metab Pharmacokinetics 1999, 14:415-424.
-
(1999)
Drug Metab Pharmacokinetics
, vol.14
, pp. 415-424
-
-
Fujino, H.1
Yamada, I.2
Kojima, J.3
-
18
-
-
3242695305
-
Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities
-
Fujino H., Saito T., Tsunenari Y., Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact 2004, 20:25-42.
-
(2004)
Drug Metabol Drug Interact
, vol.20
, pp. 25-42
-
-
Fujino, H.1
Saito, T.2
Tsunenari, Y.3
Kojima, J.4
-
19
-
-
0141997153
-
Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs
-
Kojima J., Ohshima T., Yoneda M., Sawada H. Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs. Drug Metab Pharmacokinetics 2001, 16:497-502.
-
(2001)
Drug Metab Pharmacokinetics
, vol.16
, pp. 497-502
-
-
Kojima, J.1
Ohshima, T.2
Yoneda, M.3
Sawada, H.4
-
20
-
-
11244283910
-
Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
-
Fujino H., Saito T., Tsunenari Y., et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004, 34:961-971.
-
(2004)
Xenobiotica
, vol.34
, pp. 961-971
-
-
Fujino, H.1
Saito, T.2
Tsunenari, Y.3
-
21
-
-
3242789321
-
Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase
-
Fujino H., Nakai D., Nakagomi R., et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004, 54:382-388.
-
(2004)
Arzneimittelforschung
, vol.54
, pp. 382-388
-
-
Fujino, H.1
Nakai, D.2
Nakagomi, R.3
-
22
-
-
4644364576
-
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans
-
Hirano M., Maeda K., Shitara Y., Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004, 311:139-146.
-
(2004)
J Pharmacol Exp Ther
, vol.311
, pp. 139-146
-
-
Hirano, M.1
Maeda, K.2
Shitara, Y.3
Sugiyama, Y.4
-
23
-
-
15244362340
-
Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis
-
Hui C.K., Cheung B.M., Lau G.K. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 2005, 59:291-297.
-
(2005)
Br J Clin Pharmacol
, vol.59
, pp. 291-297
-
-
Hui, C.K.1
Cheung, B.M.2
Lau, G.K.3
-
24
-
-
33745243715
-
Drug-drug interaction between pitavastatin and various drugs via OATP1B1
-
Hirano M., Maeda K., Shitara Y., Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006, 34:1229-1236.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 1229-1236
-
-
Hirano, M.1
Maeda, K.2
Shitara, Y.3
Sugiyama, Y.4
-
25
-
-
27444434929
-
Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin
-
Ando H., Tsuruoka S., Yanagihara H., et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005, 60:494-497.
-
(2005)
Br J Clin Pharmacol
, vol.60
, pp. 494-497
-
-
Ando, H.1
Tsuruoka, S.2
Yanagihara, H.3
-
26
-
-
80051625423
-
Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers
-
[Epub ahead of print] J 12
-
Inagaki Y., Hunt T., Arana B., et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 2011 January 12, [Epub ahead of print].
-
(2011)
J Clin Pharmacol
-
-
Inagaki, Y.1
Hunt, T.2
Arana, B.3
-
27
-
-
0036231636
-
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison
-
Saito Y., Yamada N., Teramoto T., et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 2002, 52:251-255.
-
(2002)
Arzneimittelforschung
, vol.52
, pp. 251-255
-
-
Saito, Y.1
Yamada, N.2
Teramoto, T.3
-
28
-
-
77749345874
-
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia
-
Sansanayudh N., Wongwiwatthananukit S., Putwai P., Dhumma-Upakorn R. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother 2010, 44:415-423.
-
(2010)
Ann Pharmacother
, vol.44
, pp. 415-423
-
-
Sansanayudh, N.1
Wongwiwatthananukit, S.2
Putwai, P.3
Dhumma-Upakorn, R.4
-
29
-
-
67249088838
-
Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia
-
Budinski D., Arneson V., Hounslow N., Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4:291-302.
-
(2009)
Clin Lipidol
, vol.4
, pp. 291-302
-
-
Budinski, D.1
Arneson, V.2
Hounslow, N.3
Gratsiansky, N.4
-
30
-
-
37349123865
-
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia
-
Lee S.H., Chung N., Kwan J., et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007, 29:2365-2373.
-
(2007)
Clin Ther
, vol.29
, pp. 2365-2373
-
-
Lee, S.H.1
Chung, N.2
Kwan, J.3
-
31
-
-
56649111325
-
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)
-
Yokote K., Bujo H., Hanaoka H., et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201:345-352.
-
(2008)
Atherosclerosis
, vol.201
, pp. 345-352
-
-
Yokote, K.1
Bujo, H.2
Hanaoka, H.3
-
32
-
-
47149104736
-
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance
-
Sasaki J., Ikeda Y., Kuribayashi T., et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008, 30:1089-1101.
-
(2008)
Clin Ther
, vol.30
, pp. 1089-1101
-
-
Sasaki, J.1
Ikeda, Y.2
Kuribayashi, T.3
-
33
-
-
69049092983
-
Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin
-
Toi T., Taguchi I., Yoneda S., et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009, 73:1466-1472.
-
(2009)
Circ J
, vol.73
, pp. 1466-1472
-
-
Toi, T.1
Taguchi, I.2
Yoneda, S.3
-
34
-
-
39749102894
-
Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function
-
Sakabe K., Fukuda N., Fukuda Y., et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008, 125:136-138.
-
(2008)
Int J Cardiol
, vol.125
, pp. 136-138
-
-
Sakabe, K.1
Fukuda, N.2
Fukuda, Y.3
-
35
-
-
0036234655
-
A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia
-
Saito Y., Yamada N., Teramoto T., et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002, 162:373-379.
-
(2002)
Atherosclerosis
, vol.162
, pp. 373-379
-
-
Saito, Y.1
Yamada, N.2
Teramoto, T.3
-
36
-
-
79952536047
-
A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes
-
Yanagi K., Monden T., Ikeda S., et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv Ther 2011, 28:160-171.
-
(2011)
Adv Ther
, vol.28
, pp. 160-171
-
-
Yanagi, K.1
Monden, T.2
Ikeda, S.3
-
37
-
-
72549107976
-
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia
-
Ose L., Budinski D., Hounslow N., Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25:2755-2764.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2755-2764
-
-
Ose, L.1
Budinski, D.2
Hounslow, N.3
Arneson, V.4
-
38
-
-
24344456373
-
A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia
-
Park S., Kang H.J., Rim S.J., et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005, 27:1074-1082.
-
(2005)
Clin Ther
, vol.27
, pp. 1074-1082
-
-
Park, S.1
Kang, H.J.2
Rim, S.J.3
-
39
-
-
67650095320
-
Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study)
-
Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 293-302
-
-
Hiro, T.1
Kimura, T.2
Morimoto, T.3
-
40
-
-
0021704422
-
Plasma lipoproteins: apolipoprotein structure and function
-
Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984, 25:1277-1294.
-
(1984)
J Lipid Res
, vol.25
, pp. 1277-1294
-
-
Mahley, R.W.1
Innerarity, T.L.2
Rall, S.C.3
Weisgraber, K.H.4
-
41
-
-
75149180515
-
Standards of medical care in diabetes-2010
-
American Diabetes Association
-
Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61. American Diabetes Association.
-
(2010)
Diabetes Care
, vol.33
, Issue.SUPPL 1
-
-
-
42
-
-
77952744253
-
High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor
-
Fukutomi T., Takeda Y., Suzuki S., et al. High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol 2010, 141:320-322.
-
(2010)
Int J Cardiol
, vol.141
, pp. 320-322
-
-
Fukutomi, T.1
Takeda, Y.2
Suzuki, S.3
-
43
-
-
0036015997
-
Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia
-
Noji Y., Higashikata T., Inazu A., et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 163:157-164.
-
(2002)
Atherosclerosis
, vol.163
, pp. 157-164
-
-
Noji, Y.1
Higashikata, T.2
Inazu, A.3
-
44
-
-
42349116146
-
Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study
-
Kawashiri M.A., Nohara A., Tada H., et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008, 83:731-739.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 731-739
-
-
Kawashiri, M.A.1
Nohara, A.2
Tada, H.3
-
45
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.H.3
-
46
-
-
33846609195
-
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis
-
Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
-
(2007)
Circulation
, vol.115
, pp. 459-467
-
-
Lorenz, M.W.1
Markus, H.S.2
Bots, M.L.3
-
47
-
-
43549105337
-
Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia
-
Mizuguchi Y., Oishi Y., Miyoshi H., et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 2008, 72:538-544.
-
(2008)
Circ J
, vol.72
, pp. 538-544
-
-
Mizuguchi, Y.1
Oishi, Y.2
Miyoshi, H.3
-
48
-
-
58249125558
-
Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy
-
Ono K., Kawasaki M., Tanaka R., et al. Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy. Ultrasound Med Biol 2009, 35:193-200.
-
(2009)
Ultrasound Med Biol
, vol.35
, pp. 193-200
-
-
Ono, K.1
Kawasaki, M.2
Tanaka, R.3
-
49
-
-
42449116679
-
Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome
-
Nakamura T., Obata J.E., Kitta Y., et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008, 51:365-371.
-
(2008)
J Cardiovasc Pharmacol
, vol.51
, pp. 365-371
-
-
Nakamura, T.1
Obata, J.E.2
Kitta, Y.3
-
50
-
-
33751400537
-
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design
-
Miyauchi H., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 2006, 70:1624-1628.
-
(2006)
Circ J
, vol.70
, pp. 1624-1628
-
-
Miyauchi, H.1
Kimura, T.2
Morimoto, T.3
-
51
-
-
78249268245
-
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study
-
Arai H., Hiro T., Kimura T., et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010, 17:1096-1107.
-
(2010)
J Atheroscler Thromb
, vol.17
, pp. 1096-1107
-
-
Arai, H.1
Hiro, T.2
Kimura, T.3
-
52
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
-
(2004)
N Engl J Med
, vol.350
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
53
-
-
52949154682
-
A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet)-Livalo Effectiveness and Safety (LIVES) Study
-
Kurihara Y., Douzono T., Kawakita K. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet)-Livalo Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther 2008, 36:709-731.
-
(2008)
Jpn Pharmacol Ther
, vol.36
, pp. 709-731
-
-
Kurihara, Y.1
Douzono, T.2
Kawakita, K.3
-
54
-
-
77952420085
-
Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia
-
Ose L., Budinski D., Hounslow N., Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210:202-208.
-
(2010)
Atherosclerosis
, vol.210
, pp. 202-208
-
-
Ose, L.1
Budinski, D.2
Hounslow, N.3
Arneson, V.4
-
55
-
-
33745255122
-
Statin use and incident nuclear cataract
-
Klein B.E.K., Klein R., Lee K.E., Grady L.M. Statin use and incident nuclear cataract. JAMA 2006, 295:2752-2758.
-
(2006)
JAMA
, vol.295
, pp. 2752-2758
-
-
Klein, B.E.K.1
Klein, R.2
Lee, K.E.3
Grady, L.M.4
-
56
-
-
34548433405
-
Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention
-
Mood G.R., Bavry A.A., Roukoz H., Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007, 100:919-923.
-
(2007)
Am J Cardiol
, vol.100
, pp. 919-923
-
-
Mood, G.R.1
Bavry, A.A.2
Roukoz, H.3
Bhatt, D.L.4
-
57
-
-
34548697581
-
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials)
-
Murphy S.A., Cannon C.P., Wiviott S.D., et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials). Am J Cardiol 2007, 100:1047-1051.
-
(2007)
Am J Cardiol
, vol.100
, pp. 1047-1051
-
-
Murphy, S.A.1
Cannon, C.P.2
Wiviott, S.D.3
-
58
-
-
27744603499
-
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
-
Pedersen T.R., Faergeman O., Kastelein J.J.P., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
-
(2005)
JAMA
, vol.294
, pp. 2437-2445
-
-
Pedersen, T.R.1
Faergeman, O.2
Kastelein, J.J.P.3
-
59
-
-
0037075262
-
Cerivastatin and reports of fatal rhabdomyolysis
-
Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539-a.
-
(2002)
N Engl J Med
, vol.346
-
-
Staffa, J.A.1
Chang, J.2
Green, L.3
-
60
-
-
80051615248
-
Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study)
-
[Epub ahead of print] N 12
-
Mizuma H., Inoue T., Takano H., et al. Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). Int J Cardiol 2010 November 12, [Epub ahead of print].
-
(2010)
Int J Cardiol
-
-
Mizuma, H.1
Inoue, T.2
Takano, H.3
|